IE45768B1 - Pharmaceutical compositions containing pirbuterol and hydroxyzinc - Google Patents

Pharmaceutical compositions containing pirbuterol and hydroxyzinc

Info

Publication number: IE45768B1
Authority: IE; Ireland
Prior art keywords: pirbuterol; hydroxyzine; composition; base; acid addition
Prior art date: 1976-08-26

Application number

IE1770/77A

Other languages

English (en)

Other versions

IE45768L (en

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-08-26

Filing date

1977-08-25

Publication date

1982-11-17

1977-08-25 Application filed by Pfizer filed Critical Pfizer

1978-02-28 Publication of IE45768L publication Critical patent/IE45768L/xx

1982-11-17 Publication of IE45768B1 publication Critical patent/IE45768B1/en

Links

VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 title claims abstract description 68
229960005414 pirbuterol Drugs 0.000 title claims abstract description 67
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 4
YVZATJAPAZIWIL-UHFFFAOYSA-M [Zn]O Chemical compound [Zn]O YVZATJAPAZIWIL-UHFFFAOYSA-M 0.000 title 1
229960000930 hydroxyzine Drugs 0.000 claims abstract description 69
ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims abstract description 68
239000000203 mixture Substances 0.000 claims abstract description 37
150000003839 salts Chemical class 0.000 claims abstract description 30
239000002253 acid Substances 0.000 claims abstract description 20
239000012458 free base Substances 0.000 claims abstract description 4
239000002585 base Substances 0.000 claims description 26
239000002552 dosage form Substances 0.000 claims description 3
230000009325 pulmonary function Effects 0.000 abstract description 5
241000124008 Mammalia Species 0.000 abstract description 4
230000002708 enhancing effect Effects 0.000 abstract 2
239000004480 active ingredient Substances 0.000 description 13
239000000243 solution Substances 0.000 description 13
239000000443 aerosol Substances 0.000 description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
239000003826 tablet Substances 0.000 description 9
XIDFCZTVVCWBGN-UHFFFAOYSA-N Pirbuterol hydrochloride Chemical compound Cl.Cl.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 XIDFCZTVVCWBGN-UHFFFAOYSA-N 0.000 description 8
229940124630 bronchodilator Drugs 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
239000003380 propellant Substances 0.000 description 8
239000000725 suspension Substances 0.000 description 7
241000282412 Homo Species 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
238000009472 formulation Methods 0.000 description 6
239000002775 capsule Substances 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000002904 solvent Substances 0.000 description 5
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
235000019441 ethanol Nutrition 0.000 description 4
239000008101 lactose Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
238000012360 testing method Methods 0.000 description 4
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
206010041349 Somnolence Diseases 0.000 description 3
239000000739 antihistaminic agent Substances 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000000168 bronchodilator agent Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
229940039009 isoproterenol Drugs 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 2
235000019739 Dicalciumphosphate Nutrition 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
244000046052 Phaseolus vulgaris Species 0.000 description 2
235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
241000534944 Thia Species 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
230000007815 allergy Effects 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
-1 decanoate dihydrochloride palmitate citrate stearate dihydrochloride succinate sulfate Chemical compound 0.000 description 2
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
229940038472 dicalcium phosphate Drugs 0.000 description 2
229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
150000008282 halocarbons Chemical class 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000011282 treatment Methods 0.000 description 2
QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
RFCAUADVODFSLZ-UHFFFAOYSA-N 1-Chloro-1,1,2,2,2-pentafluoroethane Chemical compound FC(F)(F)C(F)(F)Cl RFCAUADVODFSLZ-UHFFFAOYSA-N 0.000 description 1
RILLZYSZSDGYGV-UHFFFAOYSA-N 2-(propan-2-ylamino)ethanol Chemical compound CC(C)NCCO RILLZYSZSDGYGV-UHFFFAOYSA-N 0.000 description 1
CYXIKYKBLDZZNW-UHFFFAOYSA-N 2-Chloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)CCl CYXIKYKBLDZZNW-UHFFFAOYSA-N 0.000 description 1
235000006491 Acacia senegal Nutrition 0.000 description 1
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
244000165918 Eucalyptus papuana Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
102100033213 Teneurin-1 Human genes 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
230000000794 anti-serotonin Effects 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000003420 antiserotonin agent Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000004044 bronchoconstricting agent Substances 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
230000002741 bronchospastic effect Effects 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
235000019406 chloropentafluoroethane Nutrition 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000001609 comparable effect Effects 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
238000010908 decantation Methods 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
229960002179 ephedrine Drugs 0.000 description 1
229940050830 ephedrine / theophylline Drugs 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229940125386 long-acting bronchodilator Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
239000002609 medium Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
235000019629 palatability Nutrition 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
108010063973 teneurin-1 Proteins 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyridine Compounds (AREA)

IE1770/77A 1976-08-26 1977-08-25 Pharmaceutical compositions containing pirbuterol and hydroxyzinc IE45768B1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US71790576A	1976-08-26	1976-08-26

Publications (2)

Publication Number	Publication Date
IE45768L IE45768L (en)	1978-02-28
IE45768B1 true IE45768B1 (en)	1982-11-17

Family

ID=24883964

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IE1770/77A IE45768B1 (en)	1976-08-26	1977-08-25	Pharmaceutical compositions containing pirbuterol and hydroxyzinc

Country Status (19)

Country	Link
JP (1)	JPS5329935A (de)
AU (1)	AU503877B2 (de)
BE (1)	BE858094A (de)
CA (1)	CA1092028A (de)
DE (1)	DE2737735C3 (de)
DK (1)	DK354377A (de)
FR (1)	FR2362629A1 (de)
GB (1)	GB1541991A (de)
GR (1)	GR68687B (de)
HK (1)	HK30981A (de)
IE (1)	IE45768B1 (de)
IL (1)	IL52588A (de)
LU (1)	LU78022A1 (de)
MY (1)	MY8100263A (de)
NL (1)	NL170367C (de)
NZ (1)	NZ184746A (de)
PT (1)	PT66866B (de)
SE (1)	SE7708307L (de)
ZA (1)	ZA774474B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS63156327U (de) *	1987-04-02	1988-10-13

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2899436A (en) *		1959-08-11		chjch
US3786160A (en) *	1971-02-16	1974-01-15	Pfizer	Use of 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)-pyridines as bronchodilators
US3700681A (en) *	1971-02-16	1972-10-24	Pfizer	2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)pyridines

1977
- 1977-07-18 SE SE7708307A patent/SE7708307L/xx unknown
- 1977-07-23 GR GR54026A patent/GR68687B/el unknown
- 1977-07-25 IL IL52588A patent/IL52588A/xx unknown
- 1977-07-25 ZA ZA00774474A patent/ZA774474B/xx unknown
- 1977-07-26 NZ NZ184746A patent/NZ184746A/xx unknown
- 1977-07-28 AU AU27412/77A patent/AU503877B2/en not_active Expired
- 1977-07-29 PT PT66866A patent/PT66866B/pt unknown
- 1977-08-08 NL NLAANVRAGE7708732,A patent/NL170367C/xx not_active IP Right Cessation
- 1977-08-09 CA CA284,372A patent/CA1092028A/en not_active Expired
- 1977-08-09 DK DK354377A patent/DK354377A/da not_active Application Discontinuation
- 1977-08-22 DE DE2737735A patent/DE2737735C3/de not_active Expired
- 1977-08-23 GB GB7735281A patent/GB1541991A/en not_active Expired
- 1977-08-25 LU LU78022A patent/LU78022A1/xx unknown
- 1977-08-25 BE BE180416A patent/BE858094A/xx not_active IP Right Cessation
- 1977-08-25 JP JP10218177A patent/JPS5329935A/ja active Pending
- 1977-08-25 FR FR7725959A patent/FR2362629A1/fr active Granted
- 1977-08-25 IE IE1770/77A patent/IE45768B1/en not_active IP Right Cessation
1981
- 1981-07-02 HK HK309/81A patent/HK30981A/en not_active IP Right Cessation
- 1981-12-30 MY MY263/81A patent/MY8100263A/xx unknown

Also Published As

Publication number	Publication date
DE2737735C3 (de)	1979-10-25
PT66866B (en)	1978-12-29
DE2737735B2 (de)	1979-03-08
MY8100263A (en)	1981-12-31
DK354377A (da)	1978-02-27
ZA774474B (en)	1978-06-28
NL7708732A (nl)	1978-02-28
DE2737735A1 (de)	1978-03-02
NL170367C (nl)	1982-11-01
GR68687B (de)	1982-02-01
NZ184746A (en)	1980-02-21
JPS5329935A (en)	1978-03-20
FR2362629A1 (fr)	1978-03-24
GB1541991A (en)	1979-03-14
FR2362629B1 (de)	1980-07-11
LU78022A1 (fr)	1979-05-23
SE7708307L (sv)	1978-02-27
IE45768L (en)	1978-02-28
IL52588A (en)	1980-07-31
CA1092028A (en)	1980-12-23
PT66866A (en)	1977-08-01
IL52588A0 (en)	1977-10-31
AU2741277A (en)	1979-02-01
HK30981A (en)	1981-07-10
BE858094A (fr)	1978-02-27
AU503877B2 (en)	1979-09-27

Publication	Publication Date	Title
EP1045695B1 (de)	2004-03-24	Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
US3801631A (en)	1974-04-02	2'-hydroxy-5'-(1-hydroxy-2-(2-methyl-1-phenyl-2-propylamino)ethyl)meth-anesulfonanilide and its salts
JPH0696521B2 (ja)	1994-11-30	眼局所投与用眼圧降下剤
GB2170707A (en)	1986-08-13	An immuno-regulator
US4861783A (en)	1989-08-29	4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases
EP0099173A1 (de)	1984-01-25	Pentapeptiden für schwangere Frauen mit Schmerz und/oder Angst
EP0222575B1 (de)	1990-12-27	Prazosin-Pirbuterol-Mischung zur Bronchendilatation
EP0190851B1 (de)	1990-01-03	Entzündungshemmende Zusammensetzung
IE45768B1 (en)	1982-11-17	Pharmaceutical compositions containing pirbuterol and hydroxyzinc
US6660719B2 (en)	2003-12-09	Inhibiting T-Cell proliferation
US4175128A (en)	1979-11-20	Method for treating congestive heart failure
EP0037187B1 (de)	1986-12-10	Salze und wässrige Lösungen von 6-Methylamino-4-oxo-10-propyl-4H-pyrano(3,2-g)-chinolin-2,8-di-carbonsäure und pharmazeutische Zubereitungen, die solche Salze und Lösungen enthalten
EP0448029A2 (de)	1991-09-25	Neue pharmazeutische Verwendungen von Forskolin-Derivaten
US4623666A (en)	1986-11-18	Pharmacological applications of diphenylhalonium ion
US4714703A (en)	1987-12-22	Method of inhibiting herpetic lesions
GB2074858A (en)	1981-11-11	Compositions containing 3-deazaaden-osine
JPS648602B2 (de)	1989-02-14
US6015810A (en)	2000-01-18	Aqueous ophthalmic solution containing apafant as active ingredient
US4061756A (en)	1977-12-06	Methods for treating cardiovascular disorders
US3969508A (en)	1976-07-13	Lowering the concentration of plasma triglycerides
JPS632926A (ja)	1988-01-07	安定な、注射可能な制吐性組成物
US3821381A (en)	1974-06-28	Method of treatment
Zwickey et al.	1974	Preclinical toxicological studies of carbidopa and combinations of carbidopa and levodopa
AU609835B2 (en)	1991-05-09	Antidiabetic agent
US3798322A (en)	1974-03-19	6 or 7-substituted 4 or 8-(amino-1-methyl-butylamino)quinolines as hypolipidemic agents

Legal Events

Date	Code	Title	Description
1997-09-24	MK9A	Patent expired